LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more t…
Category: Business
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAd…
OcuTerra Announces Topline Data from Phase 2 DR:EAM Trial Evaluating Nesvategrast (OTT166 5%) for Patients with Diabetic Retinopathy
BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics announces topline data from the Phase 2 DR:EAM clinical trial.
Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India
BENGALURU, India–(BUSINESS WIRE)–The release will introduce Alcon’s latest Intraocular Lens technology in India
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $GRPH #GraphiteBio–Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced…
Nordic Eyewear Market Insights & Forecasts Report 2024-2028 with Competitive Analysis of Grand Vision, Synsam, Specsavers, Synologen, Optik Team, and Krogh Optikk – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Nordic Eyewear Market (Sweden, Denmark, Norway & Finland): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)” report has been added to ResearchAndMarkets.com’s offering. The Nordic eyewear market is…
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported it…
MediPrint® Ophthalmics Announces Successful Completion of Its Phase 2b Glaucoma Clinical Study with Positive Results.
SAN DIEGO–(BUSINESS WIRE)–MediPrint® Ophthalmics, a clinical-stage ocular drug delivery platform technology focused on transforming ocular drug delivery, announces the completion of its Glaucoma SIGHT-2, Phase 2b study. The Phase IIb trial was an act…
Vivity, la LIO à profondeur focale accrue première au monde, atteint un million d’implants
TORONTO–(BUSINESS WIRE)–Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir brillamment, annonce aujourd’hui fièrement que les lentilles intraoculaires (LIO) à profondeur focale accrue…
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
TORONTO–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpas…
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
FORT WORTH, Texas–(BUSINESS WIRE)–Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
Telios Pharma Announces Successful Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Disease
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Telios Pharma, Inc., a clinical stage biopharmaceutical company committed to improving the lives of patients with inflammatory diseases, today announced topline results from its Phase 2 study assessing TL-925, a f…
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will …
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday,…
NVISION Eye Centers' Subsidiary, NVISION Clinical Research, Rapidly Expands Under New Leadership
ALISO VIEJO, Calif.–(BUSINESS WIRE)–NVISION Eye Centers, a renowned national leader in comprehensive eye care services, proudly announces the remarkable expansion of its subsidiary, NVISION Clinical Research, LLC. Spearheaded by the visionary leaders…
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quart…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central …
GenSight Biologics annonce des communications scientifiques sur LUMEVOQ® au Congrès 2024 du NANOS
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted seven newly-hired non-executive employees stock options to purchas…